Dec. 18, 2014
On December 18, 2014 the Medicines Company, a global biopharmaceutical company focused on hospital care, and SciClone Pharmaceuticals , a U.S. based China- focused specialty pharmaceutical company, announced the establishment of a strategic partnership for two cardiovascular products in China. The partnership includes an agreement granting SciClone a license and the exclusive rights in China to promote two products of the Medicines Company:
ANGIOMAX®, an anticoagulant indicated in patients undergoing percutaneous coronary intervention (PCI), which is currently under review by the China Food and Drug Administration (CFDA) for marketing approval; and CLEVIPREX®, a third-generation dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or desirable, whose clinical trial application (CTA) for China was filed in 2013.
Under the terms of the agreement, SciClone will be responsible for all aspects of commercialization, including pre- and post-launch activities, for both products in the China market (excluding Hong Kong and Macau). SciClone has also agreed to assist in the registration process for both products in China. Total milestone payments are estimated to reach an aggregate of $50.5 million.